Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study

Ines Vandenbosch; Sander Dejongh; Kathleen Claes; Bert Bammens; Katrien De Vusser; Amaryllis Van Craenenbroeck; Dirk Kuypers; Pieter Evenepoel; Björn Meijers

doi:10.1093/ckj/sfaa228

Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study

Clin Kidney J. 2020 Nov 28;14(8):1901-1907. doi: 10.1093/ckj/sfaa228. eCollection 2021 Aug.

Authors

Ines Vandenbosch^{1

2}, Sander Dejongh³, Kathleen Claes^{2

3}, Bert Bammens^{2

3}, Katrien De Vusser^{2

3}, Amaryllis Van Craenenbroeck^{2

3}, Dirk Kuypers^{2

3}, Pieter Evenepoel^{2

3}, Björn Meijers^{2

3}

Affiliations

¹ Nephrology Unit, Ziekenhuizen Gasthuiszusters, Antwerpen, Belgium.
² Division of Nephrology, UZ Leuven, Leuven, Belgium.
³ Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.

Abstract

Background: In haemodialysis, maintaining patency of the extracorporeal circuit requires the use of anticoagulants. Although (low molecular weight) heparins are the mainstay, these are not well tolerated in all patients. Alternative approaches include saline infusion, citrate-containing dialysate, regional citrate anticoagulation or the use of heparin-coated membranes. Asymmetric cellulose triacetate (ATA) dialysers have a low degree of platelet contact activation and might be an alternative to heparin-coated dialysers. The aim of this study was to test the clotting propensity of ATA when used without systemic anticoagulation.

Methods: We performed a Phase II pilot study in maintenance dialysis patients. The 'Strategies for Asymmetrical Triacetate dialyzer heparin-Free Effective hemodialysis' (SAFE) study was a two-arm open-label crossover study. In Arm A, patients were dialysed using 1.9 m² ATA membranes in combination with a citrate-containing dialysate (1 mM). In Arm B, the ATA membrane was combined with high-volume predilution haemodiafiltration (HDF) without any other anticoagulation. The primary endpoint was the success rate to complete 4 h of haemodialysis without preterm clotting. Secondary endpoints included time to clotting and measures of dialysis adequacy.

Results: We scheduled 240 dialysis sessions (120/arm) in 20 patients. Patients were randomized 1:1 to start with Arm A or B. All patients crossed to the other arm halfway through the study. A total of 232 (96.7%) study treatments were delivered. Overall, 23 clotting events occurred, 7 in Arm A and 16 in Arm B. The success rate in Arm A (ATA + citrate-containing dialysate) was 90.8/94.0% [intention to treat (ITT)/as treated]. The success rate in Arm B (ATA + predilution HDF) was 83.3/86.2% (ITT/as treated). Time to clotting was borderline significantly better in Arm A (Mantel-Cox log rank P = 0.05).

Conclusion: ATA dialysers have a low clotting propensity and both predilution HDF and a citrate-containing dialysate resulted in high rates of completed dialysis sessions.

Keywords: anticoagulation; artificial membrane; haemodialysis; heparin-grafted membrane; regional citrate anticoagulation.